Login / Signup

Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.

Kenro HirataYasuo HamamotoMasahiko AndoChiyo K ImamuraKenichi YoshimuraKentaro YamazakiShuichi HironakaKei Muro
Published in: BMC cancer (2020)
This study was prospectively registered in the Japan Registry of Clinical Trials (jRCTs031180022, October 1, 2018).
Keyphrases
  • clinical trial
  • open label
  • phase ii
  • phase iii
  • study protocol
  • double blind
  • palliative care
  • placebo controlled
  • randomized controlled trial
  • squamous cell carcinoma
  • mesenchymal stem cells
  • replacement therapy